Search

Your search keyword '"Villemagne V"' showing total 323 results

Search Constraints

Start Over You searched for: Author "Villemagne V" Remove constraint Author: "Villemagne V"
323 results on '"Villemagne V"'

Search Results

Catalog

Books, media, physical & digital resources

4. Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome

5. F-18-PI-2620 3R Pick Tau PET Imaging in Frontotemporal Lobar Degeneration (FTLD)

6. A[Beta] Deposits in Older Non-Demented Individuals with Cognitive Decline Are Indicative of Preclinical Alzheimer's Disease

8. Tau deposition patterns are associated with functional connectivity in primary tauopathies

21. Chronic stress and Alzheimer's disease: the interplay between the hypothalamic-pituitary-adrenal axis, genetics and microglia

22. Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET

23. RP25- Sigmoid methodology allows early prediction of cognitive decline towards Alzheimer's disease across several cognitive domains

32. Binding characteristics of 18 F-PI-2620 differentiate the clinically predicted tau isoform in suspected 3/4-repeat and 4-repeat tauopathies

34. 18 F-PI2620 Tau-PET in Progressive Supranuclear Palsy – A Multi-Center Evaluation

35. Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal Injury

36. 18 F-PI2620 Tau-PET for Assessment of Heterogeneous Neuropathology in Corticobasal Syndrome

44. F-18-PI-2620 Tau-PET in Corticobasal Syndrome

45. [18F]PI-2620 Tau PET to Improve Imaging-Based Diagnosis of PSP

46. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

47. Dopamine Transporter Changes in Neuropsychiatric Disorders

48. Application of the NIA-AA research framework: Towards a biological definition of Alzheimer’s disease using cerebrospinal fluid biomarkers in the AIBL study

49. Engineered antibodies: new possibilities for brain PET?

50. Klotho allele status is not associated with Aß and APOE e4–related cognitive decline in preclinical Alzheimer's disease